Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples

Fig. 6

Correlations between pathway somatic mutation status and patient survival. No significant differences were found in progression free survival (PFS) and overall survival (OS) between patients with a MAPK pathway wild-type tumors and MAPK pathway mutated tumors; b PI3K pathway wild type and PI3K pathway mutated tumors. c Lung cancer patients with PIK3CA pathway mutated tumors had significantly poorer PFS than lung cancer patients with PI3K pathway wild-type tumors (24.95 months vs. 46 months, p = 0.0478)

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us